Silke Heinisch, MD
Dermatology · Soquel
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 3
Offices
3 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Heinisch’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
Original Medicare doctor bills
$113,565
Medicare paid this office $113,565 for 501 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 191 | $22,904 | $102 |
| Short return visit (20+ min) | 209 | $20,588 | $79 |
| Destruction of skin growth, 1-14 growths | 161 | $20,157 | $111 |
| Biopsy of related skin growth, first growth | 95 | $8,411 | $86 |
| Destruction of precancer skin growth, 1 growth | 152 | $7,508 | $47 |
See all 14 services
| Return visit (30+ min) | 191 | $22,904 | $102 |
| Short return visit (20+ min) | 209 | $20,588 | $79 |
| Destruction of skin growth, 1-14 growths | 161 | $20,157 | $111 |
| Biopsy of related skin growth, first growth | 95 | $8,411 | $86 |
| Destruction of precancer skin growth, 1 growth | 152 | $7,508 | $47 |
| New patient visit (30+ min) | 70 | $6,359 | $91 |
| Long return visit (40+ min) | 25 | $4,257 | $147 |
| New patient visit (45+ min) | 31 | $4,150 | $134 |
| Destruction of precancer skin growth, 2-14 growths | 121 | $3,923 | $7 |
| Pathology examination of tissue using a microscope, intermediate complexity | 55 | $2,931 | $20 |
| Punch biopsy, first skin growth | 15 | $2,065 | $129 |
| Destruction of skin growth, 15 or more growths | 12 | $2,035 | $136 |
| Biopsy of related skin growth, each additional growth | 22 | $1,423 | $51 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 30 | $536 | $14 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 21 | More than 75% of doctors who do this |
| Removal of skin lesions | 938 | More than 93% of doctors who do this |
| Skin biopsy | 352 | More than 92% of doctors who do this |
Who their Medicare patients are
501 Original Medicare patients in 2024. Average age 76 · Under 65 4% · 85 and older 14% · Women 62% · Also on Medicaid 6% · Health risk score 0.92. At or below the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 60% · Diabetes 19% · Coronary heart disease 17% · Chronic kidney disease 17% · Cancer 17% · Atrial fibrillation 13% · Depression 13% · Heart failure 8% · COPD 6% · Dementia 4% · Stroke 4%.
The office billed $299,134, Medicare allowed $155,620 and paid $113,565; for 1,923 services of 36 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 501 | 1,923 | 76 | 0.92 | $299,134 | $113,565 |
| 2023 | 399 | 1,517 | 74 | 0.89 | $415,454 | $105,044 |
| 2022 | 384 | 1,172 | 74 | 0.99 | $353,378 | $87,856 |
| 2021 | 420 | 1,180 | 74 | 1.07 | $352,111 | $95,590 |
| 2020 | 256 | 768 | 73 | 1.07 | $196,562 | $50,772 |
| 2019 | 247 | 690 | 72 | 0.92 | $195,952 | $46,890 |
| 2018 | 57 | 132 | 70 | 1.01 | $29,786 | $8,275 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Return visit (30+ min) | 167 | $23,134 | $105 |
| Destruction of skin growth, 1-14 growths | 110 | $16,103 | $112 |
| Short return visit (20+ min) | 145 | $15,605 | $76 |
| Biopsy of related skin growth, first growth | 91 | $9,484 | $90 |
| New patient visit (30+ min) | 72 | $6,939 | $96 |
| Destruction of precancer skin growth, 1 growth | 97 | $6,541 | $52 |
| Long return visit (40+ min) | 30 | $5,818 | $171 |
| New patient visit (45+ min) | 37 | $4,943 | $134 |
| Destruction of precancer skin growth, 2-14 growths | 75 | $2,966 | $7 |
| Biopsy of related skin growth, each additional growth | 24 | $1,834 | $52 |
| Punch biopsy, first skin growth | 12 | $1,585 | $132 |
| New patient visit (15+ min) | 29 | $1,466 | $51 |
| Short return visit | 30 | $1,350 | $45 |
2022: 13 services
| Return visit (30+ min) | 152 | $19,330 | $103 |
| Destruction of skin growth, 1-14 growths | 121 | $16,619 | $102 |
| Short return visit (20+ min) | 127 | $11,994 | $72 |
| New patient visit (30+ min) | 96 | $7,396 | $77 |
| Long return visit (40+ min) | 36 | $7,096 | $148 |
| Biopsy of related skin growth, first growth | 70 | $6,564 | $83 |
| New patient visit (45+ min) | 32 | $4,230 | $132 |
| Destruction of precancer skin growth, 1 growth | 65 | $3,936 | $49 |
| Punch biopsy, first skin growth | 13 | $1,833 | $131 |
| New patient visit (15+ min) | 27 | $1,491 | $55 |
| Destruction of precancer skin growth, 2-14 growths | 44 | $1,392 | $7 |
| Biopsy of related skin growth, each additional growth | 17 | $1,134 | $52 |
| Short return visit | 23 | $889 | $39 |
2021: 15 services
| Short return visit (20+ min) | 177 | $17,769 | $73 |
| Return visit (30+ min) | 108 | $15,509 | $116 |
| Destruction of skin growth, 1-14 growths | 108 | $14,830 | $112 |
| New patient visit (30+ min) | 105 | $9,475 | $90 |
| Biopsy of related skin growth, first growth | 87 | $9,444 | $94 |
| Long return visit (40+ min) | 26 | $4,874 | $162 |
| New patient visit (45+ min) | 32 | $4,363 | $136 |
| New patient visit (15+ min) | 61 | $3,595 | $59 |
| Punch biopsy, first skin growth | 20 | $2,763 | $132 |
| Destruction of precancer skin growth, 1 growth | 50 | $2,406 | $44 |
| Biopsy of related skin growth, each additional growth | 21 | $1,961 | $54 |
| Short return visit | 24 | $1,362 | $50 |
| Injection into skin growth, 1-7 growths | 11 | $1,052 | $50 |
| Destruction of precancer skin growth, 2-14 growths | 38 | $678 | $7 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 11 | $31 | None |
2020: 10 services
| Short return visit (20+ min) | 125 | $11,205 | $66 |
| Destruction of skin growth, 1-14 growths | 85 | $11,103 | $109 |
| New patient visit (30+ min) | 112 | $10,041 | $90 |
| Biopsy of related skin growth, first growth | 39 | $3,318 | $83 |
| Punch biopsy, first skin growth | 14 | $1,957 | $130 |
| Return visit (30+ min) | 18 | $1,910 | $101 |
| Destruction of precancer skin growth, 1 growth | 28 | $1,796 | $49 |
| New patient visit (15+ min) | 27 | $1,571 | $58 |
| Destruction of precancer skin growth, 2-14 growths | 22 | $781 | $6 |
| Short return visit | 14 | $628 | $39 |
2019: 11 services
| Destruction of skin growth, 1-14 growths | 86 | $10,923 | $104 |
| New patient visit (30+ min) | 121 | $10,350 | $86 |
| Short return visit (20+ min) | 75 | $7,457 | $64 |
| New patient visit (15+ min) | 84 | $4,899 | $58 |
| Biopsy of related skin growth, first growth | 21 | $1,664 | $76 |
| Return visit (30+ min) | 13 | $1,318 | $101 |
| Injection into skin growth, 1-7 growths | 12 | $1,109 | $46 |
| Short return visit | 23 | $992 | $40 |
| Destruction of precancer skin growth, 1 growth | 20 | $805 | $38 |
| Destruction of precancer skin growth, 2-14 growths | 16 | $318 | $5 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 12 | $38 | None |
2018: 4 services
| New patient visit (30+ min) | 33 | $3,245 | $98 |
| New patient visit (15+ min) | 19 | $1,266 | $67 |
| Destruction of skin growth, 1-14 growths | 11 | $1,229 | $112 |
| Destruction of precancer skin growth, 1 growth | 11 | $608 | $47 |
Medicaid work
$0 in 2018
Medicaid paid $0 for 52 billed services this clinician did in 2018, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 52 | $0 |
| 2018 | 52 | 1 | 14 | $0 |
Drugs they prescribed that Part D paid
$83,676
Pharmacies billed $83,676 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 632) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
603 generic and 29 brand-name prescriptions · $83,676 in drug cost · 39 antibiotic prescriptions to 32 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Clobetasol Propionate | 42 | $2,341 | $56 |
| Fluocinonide | 59 | $2,212 | $37 |
| Fluorouracil | 24 | $1,327 | $55 |
| Ketoconazole | 79 | $1,124 | $14 |
| Triamcinolone Acetonide | 63 | $830 | $13 |
See all 13 drugs
| Clobetasol Propionate | 42 | $2,341 | $56 |
| Fluocinonide | 59 | $2,212 | $37 |
| Fluorouracil | 24 | $1,327 | $55 |
| Ketoconazole | 79 | $1,124 | $14 |
| Triamcinolone Acetonide | 63 | $830 | $13 |
| Metronidazole | 17 | $797 | $47 |
| Tretinoin | 11 | $747 | $68 |
| Minoxidil | 53 | $608 | $11 |
| Clotrimazole-Betamethasone | 16 | $535 | $33 |
| Betamethasone Dipropionate | 15 | $491 | $33 |
| Mupirocin | 47 | $398 | $8 |
| Doxycycline Hyclate | 31 | $384 | $12 |
| Hydrocortisone | 41 | $313 | $8 |
Year by year
| 2024 | 632 | 271 | 0% (0) | 5% | $83,676 |
| 2023 | 722 | 231 | 0% (0) | 10% | $294,734 |
| 2022 | 602 | 207 | 0% (0) | 8% | $88,272 |
| 2021 | 710 | 230 | 0% (0) | 10% | $148,828 |
| 2020 | 572 | 177 | 0% (0) | 13% | $128,997 |
| 2019 | 389 | 166 | 0% (0) | 12% | $82,456 |
| 2018 | 622 | 281 | 0% (0) | 26% | $149,770 |
| 2017 | 825 | 353 | 0% (0) | 26% | $184,530 |
| 2016 | 637 | 282 | 0% (0) | 31% | $96,951 |
| 2015 | 289 | 154 | 0% (0) | None | $28,274 |
| 2014 | 26 | 12 | 0% (0) | None | $4,404 |
| 2013 | 17 | 13 | 0% (0) | None | $1,173 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Dupixent | 27 | $106,461 | $3,943 |
| Clobetasol Propionate | 55 | $5,296 | $96 |
| Fluocinonide | 79 | $3,696 | $47 |
| Fluorouracil | 25 | $1,541 | $62 |
| Ketoconazole | 73 | $1,351 | $19 |
| Triamcinolone Acetonide | 75 | $1,273 | $17 |
| Metronidazole | 18 | $1,214 | $67 |
| Ciclopirox | 23 | $1,096 | $48 |
| Tretinoin | 12 | $854 | $71 |
| Mupirocin | 56 | $527 | $9 |
| Doxycycline Hyclate | 26 | $511 | $20 |
| Clotrimazole-Betamethasone | 22 | $501 | $23 |
| Minoxidil | 34 | $450 | $13 |
| Spironolactone | 15 | $448 | $30 |
| Hydrocortisone | 31 | $195 | $6 |
2022: 13 drugs
| Dupixent | 14 | $50,452 | $3,604 |
| Fluocinonide | 111 | $6,257 | $56 |
| Pimecrolimus | 11 | $3,510 | $319 |
| Fluorouracil | 30 | $2,878 | $96 |
| Ketoconazole | 91 | $1,899 | $21 |
| Betamethasone Diprop Augmented | 17 | $1,420 | $84 |
| Metronidazole | 20 | $1,254 | $63 |
| Triamcinolone Acetonide | 64 | $1,187 | $19 |
| Clobetasol Propionate | 16 | $1,001 | $63 |
| Clotrimazole-Betamethasone | 16 | $522 | $33 |
| Mupirocin | 43 | $375 | $9 |
| Doxycycline Hyclate | 17 | $227 | $13 |
| Hydrocortisone | 26 | $106 | $4 |
2021: 16 drugs
| Dupixent | 13 | $44,389 | $3,415 |
| Pimecrolimus | 21 | $7,709 | $367 |
| Calcipotriene | 28 | $6,473 | $231 |
| Fluocinonide | 97 | $5,187 | $53 |
| Clobetasol Propionate | 43 | $2,905 | $68 |
| Ketoconazole | 94 | $1,808 | $19 |
| Fluorouracil | 22 | $1,635 | $74 |
| Metronidazole | 17 | $1,343 | $79 |
| Betamethasone Diprop Augmented | 31 | $1,136 | $37 |
| Triamcinolone Acetonide | 71 | $815 | $11 |
| Tretinoin | 17 | $784 | $46 |
| Desoximetasone | 12 | $571 | $48 |
| Doxycycline Hyclate | 23 | $481 | $21 |
| Mupirocin | 38 | $348 | $9 |
| Clotrimazole-Betamethasone | 11 | $296 | $27 |
| Hydrocortisone | 51 | $257 | $5 |
2020: 10 drugs
| Otezla | 12 | $45,360 | $3,780 |
| Calcipotriene | 22 | $5,391 | $245 |
| Fluocinonide | 71 | $3,802 | $54 |
| Clobetasol Propionate | 26 | $2,161 | $83 |
| Ketoconazole | 81 | $1,497 | $18 |
| Metronidazole | 18 | $1,420 | $79 |
| Triamcinolone Acetonide | 57 | $741 | $13 |
| Betamethasone Diprop Augmented | 26 | $709 | $27 |
| Mupirocin | 47 | $370 | $8 |
| Hydrocortisone | 53 | $308 | $6 |
2019: 10 drugs
| Fluocinonide | 49 | $2,853 | $58 |
| Calcipotriene | 11 | $2,258 | $205 |
| Clobetasol Propionate | 11 | $1,538 | $140 |
| Betamethasone Diprop Augmented | 22 | $944 | $43 |
| Clindamycin Phosphate | 13 | $924 | $71 |
| Ketoconazole | 42 | $738 | $18 |
| Triamcinolone Acetonide | 45 | $572 | $13 |
| Doxycycline Hyclate | 13 | $431 | $33 |
| Hydrocortisone | 40 | $226 | $6 |
| Mupirocin | 21 | $187 | $9 |
2018: 17 drugs
| Tacrolimus | 43 | $10,299 | $240 |
| Acitretin | 20 | $7,176 | $359 |
| Fluocinonide | 73 | $5,396 | $74 |
| Fluocinolone Acetonide | 48 | $4,419 | $92 |
| Betamethasone Diprop Augmented | 40 | $3,615 | $90 |
| Elidel | 12 | $3,267 | $272 |
| Clobetasol Propionate | 28 | $3,099 | $111 |
| Vectical | 21 | $2,221 | $106 |
| Metronidazole | 16 | $1,525 | $95 |
| Ketoconazole | 59 | $1,480 | $25 |
| Triamcinolone Acetonide | 56 | $1,028 | $18 |
| Retin-A | 16 | $905 | $57 |
| Desoximetasone | 11 | $888 | $81 |
| Clindamycin Phosphate | 16 | $500 | $31 |
| Hydrocortisone | 34 | $397 | $12 |
| Terbinafine | 17 | $147 | $9 |
| Mupirocin | 11 | $140 | $13 |
2017: 18 drugs
| Acitretin | 29 | $19,420 | $670 |
| Tacrolimus | 61 | $16,820 | $276 |
| Fluocinolone Acetonide | 83 | $13,062 | $157 |
| Fluocinonide | 87 | $6,703 | $77 |
| Clobex | 19 | $3,868 | $204 |
| Fluorouracil | 19 | $3,048 | $160 |
| Betamethasone Dipropionate | 26 | $2,565 | $99 |
| Ketoconazole | 88 | $2,382 | $27 |
| Metronidazole | 19 | $2,258 | $119 |
| Triamcinolone Acetonide | 93 | $2,151 | $23 |
| Clobetasol Propionate | 17 | $2,127 | $125 |
| Retin-A | 40 | $1,805 | $45 |
| Vectical | 16 | $1,692 | $106 |
| Clindamycin Phosphate | 20 | $1,204 | $60 |
| Hydrocortisone | 35 | $474 | $14 |
| Mupirocin | 27 | $395 | $15 |
| Doxycycline Monohydrate | 17 | $369 | $22 |
| Terbinafine | 20 | $283 | $14 |
2016: 12 drugs
| Acitretin | 18 | $15,087 | $838 |
| Fluocinolone Acetonide | 57 | $11,045 | $194 |
| Tacrolimus | 39 | $9,675 | $248 |
| Fluocinonide | 57 | $5,769 | $101 |
| Fluorouracil | 44 | $5,007 | $114 |
| Triamcinolone Acetonide | 85 | $2,740 | $32 |
| Clobex | 14 | $2,242 | $160 |
| Clindamycin Phosphate | 24 | $2,142 | $89 |
| Ketoconazole | 78 | $1,949 | $25 |
| Retin-A | 32 | $1,341 | $42 |
| Mupirocin | 45 | $1,037 | $23 |
| Hydrocortisone | 15 | $243 | $16 |
2015: 7 drugs
| Fluorouracil | 44 | $5,007 | $114 |
| Fluocinolone Acetonide | 21 | $3,771 | $180 |
| Tacrolimus | 15 | $3,261 | $217 |
| Fluocinonide | 19 | $1,858 | $98 |
| Triamcinolone Acetonide | 51 | $1,516 | $30 |
| Ketoconazole | 28 | $671 | $24 |
| Hydrocortisone | 13 | $212 | $16 |
Money from drug and device companies
$67 in 2025
| 2025 | 2 | 3 | None | $67 |
| 2024 | 3 | 5 | None | $87 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Verrica Pharmaceuticals | Ycanth | $36 | 2 payments
|
| Abbvie | Skyrizi | $31 | 1 payment
|
See all 3 published payments
| Verrica Pharmaceuticals | Meals · 2025-10-13 | Ycanth | $16 |
| Verrica Pharmaceuticals | Meals · 2025-08-01 | Ycanth | $20 |
| Abbvie | Meals · 2025-01-09 | Skyrizi | $31 |
See earlier years (2024)
2024: $87
| E.R. Squibb & Sons L.L.C. | Sotyktu | $34 | 1 payment
|
| Biofrontera | Ameluz | $27 | 3 payments
|
| LEO Pharma | Adbry | $26 | 1 payment
|
Professional record
- NPI
- 1649590910
- Licence
- CA 1053220, PA MT197487
- Trained
- Temple University School of Medicine, 2010
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X); Federal specialty code 207NP0225X (207NP0225X); Student in a training program (390200000X)
- Mailing address
- Po Box 276950, Sacramento, CA, 95827
- NPI first listed
- 2010-06-09
- NPI last updated
- 2024-12-03
- NPI record certified
- 2024-12-03
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2850 Telegraph Ave Ste 130, Berkeley, CA, 94705 · 800 Spruce St, Phila, PA, 19107